N/A
Completed N=701
Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap
End Stage Renal Disease (ESRD)
Source: ClinicalTrials.gov NCT02593149 ↗
Enrolled (actual)
701
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcomePrimary: Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days — 0.28; 0.75 PBCs per 1,000 CVC-days
Summary
To assess blood stream infections in participants using two FDA-cleared devices: ClearGuard HD end caps compared to the Tego® connector with the CurosTM for Tego disinfecting port protector.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Positive Blood Cultures (PBC's) Per 1,000 Central Venous Catheter (CVC)-Days |
0.28; 0.75 | — |
Eligibility Criteria
Inclusion Criteria
- All patients dialyzing with a central venous catheter
Exclusion Criteria
- Known allergy to chlorhexidine
Data sourced from ClinicalTrials.gov (NCT02593149). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.